FDA draft GFI #256B separates discretion from CGMP duties
FDA labels Draft CVM GFI #256B as not for implementation and says it contains nonbinding recommendations for comment. The draft describes a future enforcement policy for certain animal drugs compounded from bulk substances in federally registered facilities, while stating that FDA generally would not intend to exercise enforcement discretion for current good manufacturing practice violations at those facilities.
Editorial figure by RegQuality Review. Source context: FDA Draft CVM GFI #256B.
Keep draft status at the center of the record
The direct answer is that Draft CVM GFI #256B is a planning and comment record, not a current final implementation instruction. The authority record should retain the exact title, Center for Veterinary Medicine as issuing office, August 2026 draft status, docket FDA-2018-D-4533, comment deadline shown by FDA, source version, review date, and a future field for final or withdrawn status.
The FDA page says the draft is not for implementation and contains nonbinding recommendations. Systems should not translate its proposed policy into a current approved procedure, compliance flag, supplier requirement, or facility conclusion. Teams can assess potential effects while keeping current law, existing guidance, facility controls, and later agency action separate.
Model facility, product, and activity scope
The draft concerns compounding animal drugs from bulk drug substances in facilities registered under specified federal provisions. FDA also identifies exclusions, including investigational animal drugs, animal drugs compounded by a pharmacy that is not federally registered, and animal drugs compounded from FDA-approved animal or human drugs. Those distinctions belong in structured applicability records rather than a generic compounding label.
A manufacturer or compounder should preserve facility registration basis, activities, product type, ingredient source, intended animal use, applicable state status, manufacturing or compounding process, distribution, labeling, and the authority source used for each conclusion. A corporate-level facility description should not automatically determine the status of every product or operation at that location.
Enforcement discretion and CGMP remain different questions
An enforcement-discretion policy describes circumstances in which FDA may not intend to take action for specified statutory or approval-related conditions. It does not erase current good manufacturing practice duties that otherwise apply. FDA's page specifically says the agency generally would not intend to exercise enforcement discretion for CGMP violations at the covered federally registered facilities.
Quality and regulatory systems should therefore preserve the policy condition, product and activity scope, facility record, evidence, exception, decision owner, effective status, and current CGMP control separately. A record saying eligible for discretion should never become a blanket statement that the operation is compliant, exempt, approved, or beyond inspection.
Test the transition from draft to later agency action
A representative readiness review should model a federally registered facility with several product and activity types, one excluded scenario, a changed registration fact, a CGMP deviation, a comment submitted to the docket, and a later final guidance that differs from the draft. Reviewers should show which planning assumptions changed, which procedures remain current, who approved an update, and which records require reassessment without rewriting the historical draft analysis.
FDA's official page establishes the draft's identity, status, scope description, comment process, and stated relationship between future enforcement discretion and CGMP. It does not establish final policy, applicability to a particular facility or drug, lawful compounding, compliance, product quality, safety, effectiveness, or an inspection outcome. Regulated organizations retain responsibility for qualified quality, regulatory, manufacturing, veterinary, pharmacy, state-law, compliance, and legal judgment.
Enterprise buyer test
Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.
A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.
What we will watch next
RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.